Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
99.75
(
-0.90%
)
Bitcoin
74,299.86
(
0.48%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 119058

Wednesday, 05/25/2011 12:52:25 AM

Wednesday, May 25, 2011 12:52:25 AM

Post# of 257253
More on the phase-3 Tofacitinib trial called ‘ORAL Sync’ that tested DMARD ± Tofacitinib in the second-line setting:

http://finance.yahoo.com/news/Pfizer-Announces-Detailed-bw-3663629904.html?x=0&.v=1

PFE reported that this trial hit its primary endpoint in Mar 2011 (#msg-60574470). ORAL Sync is one of five registrational trials for Tofacitinib—see the prologue of #msg-62546621 for details.

Also mentioned in the above PR is a phase-2 trial of Tofacitinib ± Lipitor in patients with RA.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now